PineTree Therapeutics engages in the development of disruptive therapies in Oncology and Immuno-oncology.
PineTree Therapeutics has raised $47.0M in total funding. The most recent round was Series B. The last funding was announced in October 2025.
PineTree Therapeutics's investors include Smilegate Investment, Korea Investment Partners, SGI Venture Capital, STIC Investment, InterVest Co..
PineTree Therapeutics is headquartered in Cambridge, United States.
PineTree Therapeutics engages in the development of disruptive therapies in Oncology and Immuno-oncology.
PineTree Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PineTree Therapeutics — Funding & Investors." VCBacked, October 28, 2025, https://www.vcbacked.co/company/pinetree-therapeutics. Accessed August 18, 2026.
VCBacked. (2025). PineTree Therapeutics — Funding & Investors. Retrieved August 18, 2026, from https://www.vcbacked.co/company/pinetree-therapeutics
{{cite web |title=PineTree Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/pinetree-therapeutics |website=VCBacked |access-date=August 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated